Payment overview · 2025
General Payments
$70,531.03
109 reported records · 12 companies
Healthcare provider profile · identity verified
Danielle Lin Magness-Wellmann, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · MANKATO, MN · NPI 1679729164
Verified facts
What the public records show
CMS Open Payments records show Danielle Lin Magness-Wellmann, DO received $70,531.03 in general payments during 2025 across 109 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Auvelity, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Vraylar by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Auvelity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21,712.50 | 30.8% | 33 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20,961.56 | 29.7% | 29 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $10,890.23 | 15.4% | 16 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $6,742.34 | 9.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $5,678.94 | 8.1% | 9 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $4,368.00 | 6.2% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.52 | 0.1% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.23 | 0.1% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $33.55 | 0.1% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $18.26 | 0.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.67 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.23 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,658.50 | 17 |
| Honoraria | $18,150.00 | 4 |
| Consulting Fee | $7,397.50 | 3 |
| Travel and Lodging | $4,789.37 | 27 |
| Food and Beverage | $1,515.26 | 57 |
| Education | $20.40 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21,712.50 | 33 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20,938.50 | 26 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $10,882.42 | 15 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $6,728.48 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $5,678.94 | 9 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc., Sage Therapeutics, LLC | $4,386.26 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $52.52 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $33.55 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $23.06 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $13.86 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $7.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 168 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
140 | 24 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
168 | 22 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Duloxetine Hcl | Duloxetine Hcl | 384 | 63 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 319 | 63 |
| Lamotrigine | Lamotrigine | 319 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 314 | 51 |
| Trazodone Hcl | Trazodone Hcl | 302 | 60 |
| Bupropion Xl | Bupropion Hcl | 300 | 54 |
| Aripiprazole | Aripiprazole | 242 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 234 | 44 |
| Clonazepam | Clonazepam | 223 | 47 |
| Risperidone | Risperidone | 199 | 24 |
| Buspirone Hcl | Buspirone Hcl | 193 | 32 |
| Vilazodone Hcl | Vilazodone Hcl | 186 | 25 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 178 | 17 |
| Rexulti | Brexpiprazole | 168 | 22 |
| Sertraline Hcl | Sertraline Hcl | 165 | 26 |
| Mirtazapine | Mirtazapine | 153 | 24 |
| Memantine Hcl | Memantine Hcl | 147 | 20 |
| Gabapentin | Gabapentin | 146 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 142 | 16 |
| Vraylar | Cariprazine Hcl | 140 | 24 |
| Prazosin Hcl | Prazosin Hcl | 137 | 22 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 123 | 35 |
| Donepezil Hcl | Donepezil Hcl | 112 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 102 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 100 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 21 |
| Vyvanse | Lisdexamfetamine Dimesylate | 99 | 21 |
| Atomoxetine Hcl | Atomoxetine Hcl | 93 | 12 |
| Olanzapine | Olanzapine | 89 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 79 | 14 |
| Armodafinil | Armodafinil | 75 | 14 |
| Modafinil | Modafinil | 71 | 20 |
| Lorazepam | Lorazepam | 67 | 22 |
| Clonidine Hcl | Clonidine Hcl | 58 | suppressed |
| Topiramate | Topiramate | 55 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 48 | suppressed |
| Austedo Xr | Deutetrabenazine | 47 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 46 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 34 | suppressed |
| Ramelteon | Ramelteon | 32 | 15 |
| Methylphenidate Er | Methylphenidate Hcl | 31 | suppressed |
| Belsomra | Suvorexant | 30 | 13 |
| Lithium Carbonate Er | Lithium Carbonate | 30 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Dayvigo | Lemborexant | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 21 | suppressed |
| Abilify Maintena | Aripiprazole | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Olanzapine Odt | Olanzapine | 17 | suppressed |
| Fetzima | Levomilnacipran Hcl | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 15 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 14 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70,531.03 · 109 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, AUSTEDO XR, Auvelity, CAPLYTA, FANAPT, NUPLAZID, Qelbree, REXULTI, Sunosi, UZEDY, VRAYLAR, WAKIX, XYWAV, ZURZUVAE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error